Many older Americans on Medicare are shocked to find that the newly approved Covid shots aren't covered, leading to hefty out-of-pocket expenses. Health officials claim coverage should be available, but patients report otherwise. What's going on?
U.S. stocks fell on the first trading day of September, with major indices down. Kraft Heinz announced a split of its grocery business, and Biogen received FDA approval for a new Alzheimer's treatment. What does this mean for investors?
New Mexico's health department has issued a public order to enhance COVID-19 vaccine availability this fall after updated FDA approvals. This move aims to eliminate barriers and ensure safe vaccination for all residents.
Lilly's new oral pill, Orforglipron, has shown promising results in reducing weight and improving blood sugar levels in diabetes patients. With nearly 4% rise in shares, the drug is on track for FDA approval.
In a groundbreaking move, the Alzheimer’s Association recommends blood tests for diagnosing cognitive impairment, potentially increasing access to treatment. This could revolutionize how Alzheimer's is diagnosed, especially in rural areas.
A new Covid variant, NB.1.8.1, raises alarms for its potential to spread rapidly and evade antibodies. Meanwhile, the FDA approves a long-lasting HIV injection, and concerns about public safety arise with ICE's rule changes.
A new monoclonal antibody called clesrovimab has been recommended for infants to prevent RSV, stirring debate among health experts and advocates. The FDA approved the treatment just weeks ago.
The FDA has approved lenacapavir, a groundbreaking antiviral drug for HIV prevention developed by biochemist Wesley Sundquist. Learn how this drug could change the future of HIV treatment and prevention.
A groundbreaking HIV prevention shot, Yeztugo, has been approved by the FDA, offering hope for at-risk individuals with its twice-yearly injections. However, concerns about cost and accessibility remain.
The FDA has approved Gilead's Yeztugo, a twice-yearly injection that could revolutionize HIV prevention, boasting a 99.9% effectiveness. While hailed as a breakthrough, concerns over pricing remain, with activists urging for affordability.
